Boosting the diets of individuals with prostate cancer may offer an alternative to surgery, according to experts. An international trial showed that providing patients with supplements containing vegetables and beneficial bacteria slowed the progression of a key indicator in the blood associated with prostate cancer. This dietary intervention could potentially help patients cope with the anxiety of living with a slow-growing tumor that may not pose a threat.
Prostate cancer patients often undergo regular blood tests to measure prostate-specific antigen (PSA) levels, which can signal tumor growth. In a recent study led by Bedfordshire University, men with low-risk tumors were given a supplement comprising broccoli, turmeric, pomegranate, green tea, ginger, and cranberry. Additionally, half of the participants received a probiotic supplement containing lactobacillus, a beneficial bacteria.
The results indicated a significant slowdown in PSA progression in both groups, with even greater improvement observed in the group taking the probiotic supplement. This finding suggests the potential of dietary interventions, especially for patients with slow-growing tumors who are closely monitored by healthcare providers.
Professor Robert Thomas, the lead author of the study and a consultant clinical oncologist, highlighted that dietary changes could help men with low-risk prostate cancer remain on active surveillance, avoiding unnecessary treatments that could lead to adverse effects. The trial’s success in correlating changes in PSA levels with MRI scans is a positive development in nutritional research. Further follow-up is planned to ascertain the long-term impact of these supplements on reducing the need for major interventions such as surgery or radiotherapy.
While prostate cancer screening for high-risk individuals was rejected by UK regulators last year due to concerns of overdiagnosis, routine PSA testing is not widely offered by the NHS. The debate on the necessity of screening continues, with some advocating for broader screening criteria, especially for high-risk groups like those with a family history of the disease or Black men over 50.
The decision to refrain from widespread PSA testing stems from the potential harms associated with unnecessary treatments. Despite challenges in managing PSA levels and the tendency of patients to opt for treatment, experts emphasize the need for a cautious approach to avoid unnecessary surgeries or therapies that may not be beneficial in the long run.
In conclusion, while dietary interventions show promise in managing prostate cancer, more research is needed to fully understand their impact on treatment outcomes and patient well-being. The ongoing debate around screening protocols underscores the importance of individualized approaches to prostate cancer management based on risk factors and patient preferences.